Acerca de

hand sanitise.jpg

Impact

The ACT-Accelerator's commitment to equity remains urgent in light of persistent gaps in access to COVID-19 tools.

77 x more tests are being carried out per 1,000 people daily in high-income countries than in low-income ones


Only just over 15% of people in low-income countries have received at least one dose

 

gcat-logo-color.png

Tracking progress towards the global targets for access to COVID-19 vaccines, treatments, tests and PPE.

Funding vital research and development of new therapeutics, vaccines, and diagnostics.

Ghana testing.jpeg

Procuring 175.7 million tests and more than $767 million worth of PPE

Scientist Using Microscope

Supporting the market entry of new, affordable rapid tests.

Libya - oxygen cylinders.jpeg

Delivering more than 1.7 billion COVID-19 vaccine doses via the vaccines pillar, COVAX

COVAX pic.jpg

Procuring over US$578 million worth of medical oxygen supplies and repairing 180 PSA plants

As of: 21 Sept 2022

Read about the ACT-Accelerator's impact in our quarterly and annual reports:

act-accelerator-strategic-plan cover.png

Q2 Quarterly Update: 1 April - 30 June 2022

act-accelerator-strategic-plan cover.png

Q4 Quarterly Update: 1 October – 31 December 2021

act-accelerator-strategic-plan cover.png

Investing in the COVID-19 Response through the ACT-Accelerator: Long-Term Benefits

act-accelerator-strategic-plan cover.png

Q3 Quarterly Update: 1 July – 30 September 2021

act-accelerator-strategic-plan cover.png

Q1 Quarterly Update: 1 January – 31 March 2022

act-accelerator-strategic-plan cover.png

Q2 Quarterly Update: 1 April - 30 June 2021

act-accelerator-strategic-plan cover.png

The ACT-Accelerator: Two years of impact